FDA continues to investigate counterfeit Ozempic (semaglutide) injection 1 milligram (mg) in the legitimate U.S. drug supply chain and has seized thousands of units of the product. The agency advises wholesalers, retail pharmacies, health care practitioners and patients to check the pro
Similar Posts
Updated Company Announcement to August 28, 2025, Recall Announcement
Costa Mesa, California — February 13, 2026 — Green Lumber Holding, LLC (“Green Lumber”) is issuing an updated consumer alert regarding counterfeit products falsely marketed as genuine Green Lumber products that may pose potential health risks.WILDMAN may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use WILDMAN, a product promoted and sold for sexual enhancement on various websites, including www.loveproducts.net, and possibly in some retail stores.Glenmark Pharmaceuticals Limited – 708270 – 07/11/2025
CGMP/Finished Pharmaceuticals/AdulteratedCharles H. Harper, M.D. Norfolk, NE. EIR issued 11/13/2020
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/13/2020
Short Title (70 char) Charles H. Harper, M.D. Norfolk, NE. EIR issued 11/13/2020
FEI Number 3015685119
Firm Name Charles H. Harper, M.D.
Record Type EIR
State NE
Establishment Type Clinical InvestigatLiquid Bicarbonate Concentrate Recall: Nipro Removes MedicaLyte Liquid Bicarbonate Concentrate due to Contamination
Nipro recalls bicarbonate dialysate concentrate due to contamination. Learn about potential serious injuries, fatality risks and essential steps for healthcare providers and patients for this Class I recall.Early Alert: Infusion Set Performance Issue from BD
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program.